U.S.-based Biomarin Pharmaceutical Inc.’s treatment for one of the most common forms of dwarfism received clearance from the European Commission, becoming the first therapy to get an approval in the region for achondroplasia.
Q&A with Wendbush Securities analysts
Achondroplasia, Analysts, Annual Reports, Approvals, Biopharma/Biotech Annual Report, bluebird bio, Bristol Myers Squibb, Business, CAR-T Therapy, Clinical Trials, Issue Archives, June 2021, Med Ad News, Multiple myeloma, New Drug Approvals, Product Pipelines, R&D, TherapeuticsMed Ad News talked to Wendbush Securities analysts David Nierengarten, Laura Chico, and Liana Moussatos about various new drug approvals and other recent news updates in the industry.
Pfizer announced plans to buy Therachon, a rare disease biotech company based in Basel, Switzerland.